P1626: A SINGLE-CENTER EXPERIENCE IN INCREASING FACTOR VIII LEVELS TO ACHIEVE ZERO BLEEDING IN PATIENTS WITH SEVERE HEMOPHILIA A.

P1626: A SINGLE-CENTER EXPERIENCE IN INCREASING FACTOR VIII LEVELS TO ACHIEVE ZERO BLEEDING IN PATIENTS WITH SEVERE HEMOPHILIA A.

Bibliographic Details
Main Authors:	Rubén Clavero López, Francisco José López Jaime, Eva María Calavia Aranda, Ana María Mena Santano, Adrián Montaño, Ihosvany Fernández Bello
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000973380.85860.6b

Similar Items

Excellent hemostatic control during cardiac surgery in a patient with hemophilia B treated with albutrepenonacog alfa (rIX‐FP): A case report
by: Francisco José López‐Jaime, et al.
Published: (2023-06-01)

P1629: DISCONTINUATION OF TREATMENT WITH THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A SINGLE-CENTER CLINICAL EXPERIENCE
by: Ana María Mena Santano, et al.
Published: (2023-08-01)

Relation of bleeding patterns and factor VIII levels in children with hemophilia
by: Rina Rahardiani, et al.
Published: (2016-10-01)

TREATMENT OF BLEEDING AND FACTOR VIII INHIBITORS IN ACQUIRED HEMOPHILIA A PATIENTS
by: Peter Černelč, et al.
Published: (2004-12-01)

Management of Urgent Bleeding in Patients with Hemophilia A: Focus on the Use of Emicizumab
by: Víctor Jiménez-Yuste, et al.
Published: (2024-04-01)

P1618: REAL-WORLD DATA ON EMICIZUMAB: CORRELATION BETWEEN DRUG PLASMA LEVELS, GLOBAL PROCOAGULANT STATUS AND SPONTANEOUS JOINT ANNUALIZED BLEEDING RATE
by: Francisco José López Jaime, et al.
Published: (2023-08-01)

Acquired Hemophilia A with Gastrointestinal Bleeding
by: Narae Park, et al.
Published: (2020-01-01)

Postpartum Acquired Hemophilia Factor VIII Inhibitors and Response to Therapy
by: Volkan Karakuş, et al.
Published: (2012-05-01)

A novel cell-sheet technology that achieves durable factor VIII delivery in a mouse model of hemophilia A.
by: Kohei Tatsumi, et al.
Published: (2013-01-01)

Relationship between factor VIII levels and bleeding for rFVIII‐SingleChain in severe hemophilia A: A repeated time‐to‐event analysis
by: Laura H. Bukkems, et al.
Published: (2023-05-01)

Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A after switching to Kovaltry from other standard half‐life factor VIII concentrates
by: Kun Huang, et al.
Published: (2022-02-01)

The Need for a Bleed Type–Specific Annual Bleeding Rate in Hemophilia Studies
by: Kun Huang
Published: (2024-03-01)

Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
by: Alexandra Sherman, et al.
Published: (2017-11-01)

Expert opinion paper on the treatment of hemophilia A with emicizumab
by: Francisco-José López-Jaime, et al.
Published: (2023-12-01)

The bleeding disease : hemophilia and the unintended consequences of medical progress /
by: Pemberton, Stephen Gregory
Published: (2011)

Antithrombin inhibition using nanobodies to correct bleeding in hemophilia
by: Jamie M O'Sullivan, et al.
Published: (2020-04-01)

Bleeding phenotype in hemophilia carriers : Tunisian center experience
by: Ons Ghali, et al.
Published: (2023-01-01)

Desenvolvimento de inibidores do fator VIII na hemofilia A Development of factor VIII inhibitors in hemophilia A
by: Daniel G. Chaves, et al.
Published: (2009-01-01)

Factor VIII-Intron 1 Inversion of Hemophilia A Patients In West Anatolia
by: Pehlivan M, et al.
Published: (2007-04-01)

Potential role of a new PEGylated recombinant factor VIII for hemophilia A
by: Wynn TT, et al.
Published: (2016-06-01)

Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles
by: Chun-Yu Chen, et al.
Published: (2020-06-01)

Genetic Characterization of the Factor VIII Gene in a Cohort of Colombian Patients with Severe Hemophilia A with Inhibitors
by: Samuel Sarmiento Doncel, et al.
Published: (2022-05-01)

Acquired Hemophilia A: Bleeding Pattern and Hemostatic Therapeutic Strategies
by: Renato Marino
Published: (2023-09-01)

Authors’ Reply: “The Need for a Bleed Type–Specific Annual Bleeding Rate in Hemophilia Studies”
by: Limin Wang, et al.
Published: (2024-03-01)

Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primates
by: Michela Milani, et al.
Published: (2022-05-01)

Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study
by: Saunya Dover, et al.
Published: (2020-02-01)

Novel Severe Hemophilia A Mouse Model with Factor VIII Intron 22 Inversion
by: Jeong Pil Han, et al.
Published: (2021-07-01)

1620-1626: la “agenda” de Díaz de Rivas
by: Muriel Elvira

From the life: the art of Francis Barlow (c.1626-1704)
by: Flis, NJB
Published: (2012)

Vázquez de Hinostroza y de artes, Diego (1626-?)
by: Gregorio Delgado García
Published: (2008-06-01)

Vázquez de Hinostroza y de artes, Diego (1626-?)
by: Gregorio Delgado García
Published: (2008-06-01)

Evaluating the potential bioactivity of a novel compound ER1626.
by: Lijun Wang, et al.
Published: (2014-01-01)

Joint Dysfunction as a Cause of Spontaneous Subclinical Bleeding in Infants with Hemophilia
by: Elena Anna Boccalandro, et al.
Published: (2023-10-01)

Frequency of hemophilia and hemostatic evaluation in persons with bleeding symptoms in Southeast, Nigeria
by: Samuel Okparaoka, et al.
Published: (2019-01-01)

Study of bleeding disorders (hemophilia) in children in Beni-Suef university hospital
by: Dalia Kamal, et al.
Published: (2022-10-01)

Perioperative Outcomes of Patients with Bleeding Disorders Undergoing Major Surgery at an Academic Hemophilia Treatment Center
by: Ruben Rhoades MD, MS, et al.
Published: (2023-03-01)

A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy
by: Alex C. Chen, et al.
Published: (2020-04-01)

Factor VIII Level in Mothers of Patients with Severe Hemophilia A and its Impact on Joint Status
by: Iman Ragab, et al.
Published: (2023-01-01)

Incidence of factor VIII inhibitory antibodies in patients with hemophilia A seen at HEMOCE, Ceará, Brazil
by: Rosineide A Carvalho, et al.

Recombinant factor&nbsp;VIII in the management of hemophilia A: current use and future promise
by: Jerry S Powell
Published: (2009-05-01)